New medicine being tested?

[Guest guest]

I got a letter from the national psoriasis foundation talking about if I

wanted to participate in a new study.....I never heard of this medication

before.....Its called - Anti-CD11a (monoclonal antibody) anybody try or hear

about this stuff yet?? thanks......

[Guest guest]

Hi Newjersey,

I looked it up on the net. You can link to the XOMA's web site

(http://www.xoma.com/). They are the drug manufacturer. Here is an

excerpt from one of XOMA's earlier studies:

http://lahaaland.com/science/medicine/medicine85.html

bruce ( A fellow New Jersey Guy)

" XOMA Investigator Presents Positive Results From Phase II Psoriasis

Study of Hu1124/ Anti-CD11a Antibody Product At Canadian Dermatology

Association August 3. 1999

A XOMA investigator has presented positive results from a Phase II

clinical study of the hu1124 (antiCD11a) antibody product in moderate

to severe psoriasis patients. The product is being developed under a

collaboration between XOMA Ltd. (Nasdaq:XOMA) and Genentech, Inc. The

data were presented for the first time by Kim Papp, MD, a study

investigator, on July 2 at the Canadian Dermatology Association

meeting in Vancouver, British Columbia.

" The data demonstrate that hu1124 shows significant activity in

patients with moderate-to-severe plaque psoriasis, " said Dr. Papp,

Clinical Investigator at Probity Medical Research in Ontario. " These

results are further evidence that this compound may inhibit the

inflammatory process in psoriasis without depleting T cells and

suppressing the immune system. "

Psoriasis in its various forms is one of the most common skin

diseases worldwide. In North America and Europe up to a million

people may be affected by the more severe forms of the disease.

People with moderate-to-severe plaque psoriasis suffer chronic or

recurring bouts of skin inflammation characterized by an accumulation

of abnormally fast-growing keratinocyte skin cells that result in

red, raised, scaly plaques.

Psoriasis is now considered to be a T cell-mediated chronic

inflammatory disorder. T cells are specialized white blood cells

mobilized by the immune system to destroy foreign cells. In

psoriasis, increased activation, adhesion and migration of T cells

into the skin contribute to the inflammation and abnormal

keratinocyte proliferation. Misdirected T cell activities also play

an important role in other autoimmune diseases, such as rheumatoid

arthritis, multiple sclerosis, and inflammatory bowel disease.

XOMA Ltd. develops and manufactures biopharmaceuticals at facilities

located in Berkeley and Santa , California. The company's

medical targets include bacterial and fungal infections, infectious

complications (such as those that may follow trauma or surgery),

immunologic and inflammatory disorders " .

> I got a letter from the national psoriasis foundation talking

about if I wanted to participate in a new study.....I never heard of

this medication before.....Its called - Anti-CD11a (monoclonal

antibody) anybody try or hear about this stuff yet?? thanks......